IMproved exercise tolerance in patients with PReserved Ejection fraction by Spironolactone on myocardial fibrosiS in Atrial Fibrillation rationale and design of the IMPRESS-AF randomised controlled trial by Shantsila, Eduard et al.
 
 
University of Birmingham
IMproved exercise tolerance in patients with
PReserved Ejection fraction by Spironolactone on
myocardial fibrosiS in Atrial Fibrillation rationale
and design of the IMPRESS-AF randomised
controlled trial
Shantsila, Eduard; Haynes, Ronnie; Calvert, Melanie; Fisher, James; Kirchhof, Paulus; Gill,
Paramjit S; Lip, Gregory Y H
DOI:
10.1136/bmjopen-2016-012241
License:
Creative Commons: Attribution (CC BY)
Document Version
Publisher's PDF, also known as Version of record
Citation for published version (Harvard):
Shantsila, E, Haynes, R, Calvert, M, Fisher, J, Kirchhof, P, Gill, PS & Lip, GYH 2016, 'IMproved exercise
tolerance in patients with PReserved Ejection fraction by Spironolactone on myocardial fibrosiS in Atrial
Fibrillation rationale and design of the IMPRESS-AF randomised controlled trial', BMJ open, vol. 6, no. 10, pp.
e012241. https://doi.org/10.1136/bmjopen-2016-012241
Link to publication on Research at Birmingham portal
Publisher Rights Statement:
Checked for eligibility: 20/10/2016.
This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which
permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See:
http://creativecommons.org/licenses/by/4.0/
General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the
copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes
permitted by law.
•	Users may freely distribute the URL that is used to identify this publication.
•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private
study or non-commercial research.
•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•	Users may not further distribute the material nor use it for the purposes of commercial gain.
Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
When citing, please reference the published version.
Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been
uploaded in error or has been deemed to be commercially or otherwise sensitive.
If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to
the work immediately and investigate.
Download date: 01. Mar. 2020
IMproved exercise tolerance in patients
with PReserved Ejection fraction by
Spironolactone on myocardial ﬁbrosiS
in Atrial Fibrillation rationale and
design of the IMPRESS-AF randomised
controlled trial
Eduard Shantsila,1 Ronnie Haynes,1 Melanie Calvert,2 James Fisher,3
Paulus Kirchhof,1,4 Paramjit S Gill,2 Gregory Y H Lip1
To cite: Shantsila E,
Haynes R, Calvert M, et al.
IMproved exercise tolerance
in patients with PReserved
Ejection fraction by
Spironolactone on myocardial
fibrosiS in Atrial Fibrillation
rationale and design of the
IMPRESS-AF randomised
controlled trial. BMJ Open
2016;6:e012241.
doi:10.1136/bmjopen-2016-
012241
▸ Prepublication history and
additional material is
available. To view please visit
the journal (http://dx.doi.org/
10.1136/bmjopen-2016-
012241).
Received 12 April 2016
Revised 7 July 2016
Accepted 8 September 2016
For numbered affiliations see
end of article.
Correspondence to
Professor Gregory YH Lip;
g.y.h.lip@bham.ac.uk
ABSTRACT
Introduction: Patients with atrial fibrillation frequently
suffer from heart failure with preserved ejection
fraction. At present there is no proven therapy to
improve physical capacity and quality of life in
participants with permanent atrial fibrillation with
preserved left ventricular contractility.
Objective: The single-centre IMproved exercise
tolerance In heart failure With PReserved Ejection
fraction by Spironolactone On myocardial fibrosiS In
Atrial Fibrillation (IMPRESS-AF) trial aims to establish
whether treatment with spironolactone as compared
with placebo improves exercise tolerance
(cardiopulmonary exercise testing), quality of life and
diastolic function in patients with permanent atrial
fibrillation.
Methods and analysis: A total of 250 patients have
been randomised in this double-blinded trial for 2-year
treatment with 25 mg daily dose of spironolactone or
matched placebo. Included participants are 50 years
old or older, have permanent atrial fibrillation and
ejection fraction >55%. Exclusion criteria include
contraindications to spironolactone, poorly controlled
hypertension and presence of severe comorbidities
with life expectancy <2 years. The primary outcome is
improvement in exercise tolerance at 2 years and key
secondary outcomes include quality of life (assessed
using the EuroQol EQ-5D-5L (EQ-5D) and Minnesota
Living with Heart Failure (MLWHF) questionnaires),
diastolic function and all-cause hospitalisation.
Ethics and dissemination: The study has been
approved by the National Research and Ethics
Committee West Midlands—Coventry and
Warwickshire (REC reference number 14/WM/1211).
The results of the trial will be published in an
international peer-reviewed journal.
Trial registration numbers: EudraCT2014-003702-
33; NCT02673463; Pre-results.
INTRODUCTION
Heart failure (HF) with preserved ejection
fraction (HFpEF) is an emerging problem of
modern cardiology, represents about half of
all cases of HF, and is very common in indivi-
duals with atrial ﬁbrillation (AF).1–3 In the
Framingham Heart Study, 37% of partici-
pants with new AF had HF and presence of
AF was strongly related to incident HFpEF
(HR 2.34, 95% CI 1.48 to 3.70).4 Despite
preservation of left ventricular ejection frac-
tion (LVEF), patients with HFpEF have poor
quality of life, high morbidity and mortality;
largely comparable to HF with reduced
LVEF.5 Improvements in morbidity and mor-
tality with conventional treatments used in
HF with reduced LVEF, however, have not
translated to HFpEF.6
AF is present in about 40% of participants
with HFpEF and is associated with higher
N-terminal pro b-type natriuretic peptide
(NT-proBNP) levels, risk of death and hos-
Strengths and limitations of this study
▪ Double-blinded randomised placebo-controlled
study design.
▪ Accurate assessment of exercise tolerance (the
primary outcome) using cardiopulmonary exer-
cise testing.
▪ Recruitment from primary and secondary care
settings to provide a representative population of
patients.
▪ Single-centre study.
▪ Assessment of effect of the treatment for mortal-
ity is beyond the study statistical power.
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pital admission with HF.7–10 In the Candesartan in Heart
failure-Assessment of Reduction in Mortality and mor-
bidity (CHARM) programme, AF was associated with
increased risk of death or hospitalisation for worsening
HFpEF (HR 1.72, 95% CI 1.45 to 2.06 for adverse car-
diovascular outcomes).8
The mechanisms leading to symptoms, morbidity and
mortality in patients with HFpEF and AF are poorly
understood. Under physiological conditions, left ven-
tricular pressure rapidly decays after systole, allowing low
ﬁlling pressures and adequate diastolic ﬁlling. In HFpEF,
the diastolic ﬁlling is compromised as a result of aggrava-
tion in active and passive relaxation (increased cardiac
stiffness).11 This ventricular ﬁlling abnormality, in turn,
reduces cardiac output leads to symptoms of HF.1 This
theory is supported by interventional experiments and
by large population-based studies carried out using a
non-invasive approach to measure diastolic stiffness.12–14
Furthermore, the elevated ﬁlling pressure will increase
pressure in the pulmonary system and eventually lead to
pulmonary hypertension and pulmonary oedema in
acute settings. A stiff ventricle may possess only limited
ability to use the Frank-Starling mechanism to increase
stroke volume during exercise with increasing heart
rates.15
While activation of proﬁbrotic pathways is a known
response to increased pressure load in the heart,
increased production of myocardial collagen and devel-
opment of ﬁbrosis can also aggravate diastolic dysfunc-
tion and ventricular stiffness. Increased myocardial
collagen turnover and shift in the balance between
matrix metalloproteinases and their inhibitors also
favour of excessive myocardial ﬁbrosis.16 17
Aldosterone is an important promoter of left ventricu-
lar ﬁbrosis.18 Mechanisms of aldosterone-mediated
cardiac ﬁbrosis include myocardial inﬂammation, oxida-
tive stress, and cardiomyocyte apoptosis and also direct
stimulation of cardiac ﬁbroblasts to produce colla-
gen.19 20 Cardiac expression of mineralocorticoid recep-
tors is increased in AF, thus augmenting the genomic
effects of aldosterone.21
The effectiveness of spironolactone in HFpEF has
been tested recently in two clinical trials. The
Aldosterone Receptor Blockade in Diastolic Heart
Failure (ALDO-DHF) study mainly enrolled participants
with hypertensive, another major risk factor for
HFpEF.22 23 While 92% of the trial patients had hyper-
tension, only 5% of the study population (n=22) had AF
at presentation.22 23 The Treatment of Preserved Cardiac
Function Heart Failure With an Aldosterone Antagonist
(TOPCAT) study24 25 included a higher proportion of
participants with AF (mainly paroxysmal AF). The study
deﬁned preserved left ventricular function as
LVEF≥45%, thus recruiting a proportion of participants
with impaired LVEF according to contemporary deﬁni-
tions (also called ‘HF with intermediate ejection frac-
tion’ by some).1 26 Thus, the current evidence on the
effectiveness of spironolactone in patients with AF with
preserved LVEF on morbidity and quality of life is
sparse. We, therefore, plan the IMproved exercise toler-
ance In heart failure With PReserved Ejection fraction
by Spironolactone On myocardial ﬁbrosiS In Atrial
Fibrillation (IMPRESS-AF) trial to determine the effects
of spironolactone in permanent AF with preserved
LVEF.
Study objectives
The IMPRESS-AF trial aims to establish whether, in parti-
cipants with permanent AF, treatment with spironolac-
tone as compared with placebo will improve exercise
tolerance as a surrogate for cardiovascular mortality/
morbidity (primary outcome); and will improve quality
of life and diastolic function, as well as reduce the rate
of all-cause hospital admissions, and increase rate of
spontaneous cardioversion to sinus rhythm (secondary
outcomes). The IMPRESS-AF trial will provide evidence
on the clinical effectiveness of a readily available treat-
ment in participants with AF with preserved LVEF.
Study design
The IMPRESS-AF is a double-blinded, randomised,
placebo-controlled single-centre trial conducted in
Birmingham, UK. The trial aims to recruit 250 partici-
pants permanent AF and LVEF>55% from primary and
secondary care to be randomised to either spironolac-
tone or placebo. Recruitment of the planned 250
patients was completed on 29 June 2016. The trial proto-
col was developed following the Standard Protocol Items
for Randomized Trials (SPIRIT) statement and the latest
patient-reported outcome (PRO)-speciﬁc guidance from
the International Society for Quality of Life Research
(ISOQOL) Best Practice for PROs in trials taskforce.27–29
The full protocol is available (see online supplementary
appendix 1).
Eligibility
The main inclusion and exclusion criteria are sum-
marised in table 1. Eligible patients are of male or
female gender and age of 50 years or older. Permanent
AF is deﬁned by the European Society of Cardiology cri-
teria.30 31 All participants have LVEF>55% as established
by echocardiography during the screening.32 The pro-
spective participants must be able to perform cardiopul-
monary exercise testing using a cycling ergometer and
complete quality of life questionnaires in English in
their native language. For this, an interpreter and trans-
lated materials are provided if English is not their
spoken language. Average values from 10 consecutive
cardiac cycles are calculated to establish LVEF and ratio
of peak velocities of early diastolic mitral inﬂow and
peak early tissue Doppler velocity (E/e’). In patients
with hypertension, antihypertensive treatment was estab-
lished before the recruitment and patients with systolic
blood pressure more than 160 mm Hg were excluded.
To improve generalisability, we do not include a
requirement for evidence of diastolic dysfunction, as the
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trial patients would have impaired diastolic function due
to AF. The principal exclusion criteria are designed to
exclude patients with contraindications to spironolac-
tone or signiﬁcant comorbidities, which would prevent
the prospective participants from completion of the
study without relation to the study objectives. All partici-
pants will receive current optimised treatment following
established clinical guidelines on management of AF,
HF and hypertension.1
Trial setting and identification of participants
The trial is coordinated by Primary Care Research and
Clinical Trials Unit (PC-RCTU), University of
Birmingham, including coordination of the participant
searches, using clinical research network. All patients
are seen, investigated and managed in the Research
Clinic in the Institute of Cardiovascular Sciences
(RC-ICS), City Hospital, Birmingham.
Trial participants have been recruited from primary
care AF registers in family practices and outpatient AF
clinics in Sandwell and West Birmingham Hospitals
Trust, Birmingham. This allowed enrolment of a repre-
sentative population of patients with AF. At the screening
visit to the RC-ICS participants were consented into the
study and screened for eligibility. During the baseline
visit, the eligible patients undergone cardiopulmonary
exercise testing using a cycling ergometer (to measure
peak oxygen consumption (VO2)), 6 min walk test and
complete quality of life questionnaires (validated
Minnesota Living with Heart Failure (MLWHF)33–35 and
EuroQol EQ-5D-5L (EQ-5D)36 37 questionnaires). After
that, they were randomised into the 2-year trial. The
study schema and visit schedule are shown in ﬁgure 1
and table 2.
Randomisation and blinding
During randomisation (1:1), the participants were ﬁrst
stratiﬁed by their baseline peak VO2 (two stratiﬁcation
groups; VO2≤16 mL/min/kg, and VO2>16 mL/min/
kg). A secure web-based randomisation system was used
for the concealed allocation of a unique investigational
medicinal product number to each participant. Trial
participants, the trial team in contact with the patient,
care providers, outcome assessors and data analysts all
remain blinded to the treatment.
Blinding of the trial drug identity took place at the
time of packaging and labelling (Catalent Pharma
Solutions, UK). Only the database programmer and the
Catalent Pharma Solutions can see the investigational
medicinal product number list. A sealed copy of the list
is kept to the Pharmacy Department at City Hospital
(who are independent of the trial, and operate 24 hours
a day). In the event of a codebreak situation occurring,
the patient will be withdrawn from the trial treatment, as
they will become unblinded to their trial drug.
Treatment and dosing schedule
Trial participants receive either spironolactone 25 mg
once daily or matched placebo. This dose has been
shown to improve outcomes in systolic HF, improve dia-
stolic function in HFpEF and to reduce collagen turn-
over, a marker for ﬁbrotic signalling, in the The
Randomized Aldactone Evaluation Study (RALES)
population.38 The same dose of the spironolactone
Table 1 Key eligibility criteria for IMPRESS-AF
Inclusion criteria Exclusion criteria
Permanent AF LVEF<55% (echocardiography)
Age 50 years old or over Severe systemic illness (life expectancy <2 years)
Ability to understand and complete questionnaires (with
or without use of a translater/translated materials)
Severe COPD (eg, requiring home oxygen or chronic oral steroid
therapy)
Severe mitral/aortal valve stenosis/regurgitation
Significant renal dysfunction (serum creatinine 220 µmol/L or
above), anuria, active renal insufficiency, rapidly progressing or
severe impairment of renal function, confirmed or suspected renal
insufficiency in patients with diabetes/diabetic nephropathy
Increase in potassium level to >5 mmol/L
Recent coronary artery bypass graft surgery (within 3 months)
Use of aldosterone antagonist within 14 days before randomisation
Use of or potassium sparing diuretic within 14 days before
randomisation
Systolic blood pressure >160 mm Hg
Addison’s disease
Hypersensitivity to spironolactone or any of the ingredients in the
product
Any participant characteristic that may interfere with adherence to
the trial protocol
AF, atrial fibrillation; COPD, chronic obstructive pulmonary disease; IMPRESS-AF, IMproved exercise tolerance In heart failure With
PReserved Ejection fraction by Spironolactone On myocardial fibrosiS In Atrial; LVEF, left ventricular ejection fraction.
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within 1 year signiﬁcantly improved diastolic function in
participants with HFpEF from the ALDO-DHF trial.23
In the case of an increase in potassium level to 5.1–
5.5 mmol/L or in the presence of other
non-life-threatening side effects (such as gynaecomastia)
the trial drug is downtitrated to 25 mg each second day.
In such cases, the investigators are advised to reuptitrate
the trial medication if the reason for downtitration has
resolved.
Drug toxicity will be deﬁned as an increase in potas-
sium level to >5.5 mmol/L. In the case of toxicity or sus-
pected toxicity, the trial medication will be stopped for
the duration of the trial, but the patient will be
requested to attend the remaining follow-up visits. Blood
pressure will be controlled during the duration of the
study with particular attention to blood pressure levels
after beginning of the study drug and after any changes
in antihypertensive agents and their doses.
Study end points
The primary efﬁcacy end point will be the improvement
in exercise tolerance at 2 years. This will be assessed by
the difference between trial groups in peak VO2 on car-
diopulmonary exercise testing.
The secondary efﬁcacy end point will be the level of
improvement in quality of life and diastolic function,
and also the improvement the rate of all-cause hospital
admissions and spontaneous return the sinus rhythm,
with spironolactone. This will be assessed by: (1)
improvement in exercise tolerance measured by 6 min
walking test (a simple test of exercise performance) at
baseline and at 2 years; (2) improvement in quality of
life (MLWHF and EQ-5D36 37 questionnaires) over the
2-year duration; (3) improvement in left ventricular dia-
stolic function (E/e’ ratio39–45 on echocardiography)
will be assessed at baseline and at 2 years; (4) improve-
ment in rates of all-cause hospitalisations during 2-year
follow-up;35 36 (5) spontaneous return to sinus rhythm
on ECG after 2 years of treatment. Additionally we will
record any cases of major adverse clinical events, such as
death from any causes, death from cardiac causes, hospi-
talisation for cardiac causes, a change in the New York
Heart Association (NYHA) class, stroke or systemic
thromboembolism.
The study started on the October 2014 and recruit-
ment completed on 29 June 2016. We plan to complete
the study by September 2018.
Statistical considerations
The analysis will follow intention-to-treat principles. The
linear mixed-model analysis will be used to compare
peak VO2 at 2 years between the intervention and the
control group. Covariates will be peak baseline VO2, age,
gender, systolic/diastolic blood pressure and body mass
index measured at baseline. General practitioner prac-
tices or recruitment centres will be included as random
effects.
Secondary analyses will also use linear or non-linear
mixed modelling as above but with the dependent vari-
able the secondary end points mentioned in the earlier
Trial end points section. Interactions between interven-
tion/control, age and gender will also be included in
the mixed modelling analyses to see whether differences
in secondary end points between intervention and
control participants vary with these two factors. Missing
values will be substituted using a multiple imputation
Figure 1 Trial schema. BNP, brain natriuretic peptide; CPET, cardio-pulmonary exercise testing; eGRF, estimated glomerular
filtration rate; FBC, full blood count and haematocrit; GP, general practitioner; QoL, quality of life; RC-CCS, Research clinic of the
University of Birmingham Institute for Cardiovascular Sciences, City Hospital, Birmingham, UK.
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Table 2 Timeline of trial procedures alongside the assessments that will be carried out at each stage
Follow-up
Visit Screening Baseline
Month
1
Month
3
Month
6
Month
9
Month
12
Month
15
Month
18
Month
21
Month
24
Additional visits will be arranged to reassess potassium levels if patient’s blood results show a
potassium level of >5.0 mmol/L
Eligibility check X X
Informed consent X
Relevant medical history taken X
Concomitant medication X X X X X X X X X X X
Standard clinical examination including BP
check
X X X X X X X X X X X
Clinical biochemistry
Full blood count X X X X X X X X X X
Renal function, potassium, sodium X X X X X X X X X X
HbA1c (for diabetics) X
Lipid levels X
ECG X X
Echocardiogram X X
Brain natriuretic peptide test X X
Randomisation X
Dispensing of study drug X X X X
Cardiopulmonary exercise testing X X
6 min walk test X X
Quality of life questionnaires X X X
BP, blood pressure; HbA1c, glycated haemoglobin.
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procedure. Because of the likelihood of non-normality,
the method of Hussain et al46 will be used.
For the primary outcome, we based our power calcula-
tion for peak VO2 on the published values of peak VO2
in participants with HF (16±5 mL/min/kg).47 We antici-
pate a difference of 2 mL/min/kg in the improvement
in peak VO2 after 2-year treatment with spironolactone
compared with the control group. Published data in
HFpEF suggest that such a difference would be clinically
relevant and it was factored for the design of the recent
ALDO-DHF study of spironolactone in patients with
HFpEF, 95% of whom were free from AF.22 23 48
Unfortunately, the study by Cicoira et al47 used for power
calculation does not give a SD of the change in peak
VO2 from the baseline but a similar trial, Edelmann
et al49 provides that statistic (5 mL/min/kg) and also
reports a similar magnitude of the effect. We estimate
that a sample size of 100 participants in each arm would
give the power of at least 80% to detect differences in
primary and secondary end points of a magnitude con-
sistent with published results from similar studies. The
inclusion of a provision for a 20% drop out rate could
potentially lead to powers of near 90% or more if the
assumption of a drop rate of 20% were too pessimistic.
Study funding and management
The IMPRESS-AF trial is funded by the National
Institute for Health Research (NIHR), UK. The
University of Birmingham is the sponsor of this trial.
The day-to-day management of the trial will be coordi-
nated by the Primary Care Research and Clinical Trials
Unit (PC-CRTU) at the University of Birmingham, regis-
tered by the NIHR as a trials unit. The Trial
Management Group will meet at least monthly to ensure
implementation of the trial. A Trial Steering Committee
has been appointed and will be responsible for oversee-
ing the progress of the trial. An independent Data
Monitoring and Ethics Committee will be responsible
for the regular monitoring of trial data and it will give
advice on whether the accumulated data from the trial,
together with the results from other relevant research,
justify the continuing recruitment of further partici-
pants. The Data Monitoring and Ethics Committee will
make conﬁdential recommendations to the Trial
Steering Committee as the decision-making committee
for the trial.
Ethics and dissemination of findings
The results of the trial will be published in an inter-
national peer-reviewed journal. We hope that the study
ﬁndings will inform future guidelines for management
of HF.
Registration: The study is registered with European
Union Clinical Trials Register (EudraCT number
2014-003702-33), clinicaltrial.gov (NCT02673463) and
has been adopted by the NIHR Clinical Research
Network.
DISCUSSION
AF has a prominent role in prognostication in HF. In a
recent large study of 23 644 participants with HF, of
which 48.3% had documented AF, the presence of the
arrhythmia was associated with higher adjusted rates of
ischaemic stroke, hospitalisation for HF, all-cause hospi-
talisation and death irrespectively whether LVEF was
impaired or preserved.50 Clinical trials of aldosterone
antagonists (RALES, The Eplerenone Post–Acute
Myocardial Infarction Heart Failure Efﬁcacy and Survival
Study (EPHESUS), The Eplerenone Post–Acute
Myocardial Infarction Heart Failure Efﬁcacy and Survival
Study (EMPHASIS-HF)) uniformly showed their clinical
beneﬁts in systolic HF. However, there is no established
treatment for patients with AF with HFpEF.
Activation of aldosterone pathway can contribute to
the progression of patients with AF to symptomatic HF
despite preserved cardiac contractility, due to the pro-
motion of cardiac ﬁbrosis. Published evidence from AF
populations supports the central role of atrial ﬁbrosis in
electrical and structural atrial remodelling, and its inde-
pendent predictive value for the high risk of cerebrovas-
cular events.51 52 There is an association between AF
and abnormal left ventricular ﬁbrosis, which related to
the depressed diastolic function in such participants.53
According to a substudy of the RALES trial, the
improved survival in participants treated by spironolac-
tone was linked to its ability to reduce serum markers of
ongoing ﬁbrosis (type I and III collagen synthesis).38
Additionally, aldosterone leads to cardiac invasion by
proinﬂammatory mononuclear cells.54 Aldosterone
antagonists (ie, spironolactone or eplerenone) amelior-
ate left ventricular ﬁbrosis in animal models and reduce
levels of serum markers of collagen turnover in humans
with HFpEF (n=44).55 56 In a small, published pilot trial,
spironolactone reduced left ventricular ﬁbrosis and
improved diastolic function in participants with HFpEF
(dilated cardiomyopathy, n=25).57
The randomised IMPRESS-AF study should help
understanding utility of aldosterone inhibition in per-
manent AF for prevention of deterioration or improve-
ment in exercise tolerance and quality of life as well as
in cardiac diastolic function.
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